F901318 (olorofim) is a novel antifungal drug that is highly active against species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the pyrimidine biosynthesis pathway. In this study, the antifungal effects of F901318 against were investigated. Live cell imaging revealed that, at a concentration of 0.1 μg/ml, F901318 completely inhibited germination, but conidia continued to expand by isotropic growth for >120 h. When this low F901318 concentration was applied to germlings or vegetative hyphae, their elongation was completely inhibited within 10 h. Staining with the fluorescent viability dye bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC) showed that prolonged exposure to F901318 (>24 h) led to vegetative hyphal swelling and a decrease in hyphal viability through cell lysis. The time-dependent killing of F901318 was further confirmed by measuring the fungal biomass and growth rate in liquid culture. The ability of hyphal growth to recover in drug-free medium after 24 h of exposure to F901318 was strongly impaired compared to that of the untreated control. A longer treatment of 48 h further improved the antifungal effect of F901318. Together, the results of this study indicate that F901318 initially has a fungistatic effect on isolates by inhibiting germination and growth, but prolonged exposure is fungicidal through hyphal swelling followed by cell lysis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105813 | PMC |
http://dx.doi.org/10.1128/AAC.00231-18 | DOI Listing |
BMC Infect Dis
December 2024
Department of Haematology, Department of Microbiology, Immunology and Transplantation, University Hospitals Leuven, KU Leuven, Herestraat 49, Leuven, 3000, Belgium.
Antimicrob Agents Chemother
November 2024
Division of Infectious Diseases, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
We evaluated the activity of olorofim against species. Olorofim demonstrated potent activity against all isolates tested with a minimum inhibitory concentration (MIC) range ≤0.008-0.
View Article and Find Full Text PDFBMC Infect Dis
November 2024
Department of Haematology, Department of Microbiology, Immunology and Transplantation, University Hospitals Leuven, KU Leuven, Herestraat 49, Leuven, 3000, Belgium.
There is clearly a need for novel antifungal agents, not only concerning spectrum, but also oral bioavailability, tolerability, and drug-drug interactions. There is growing concern for antifungal resistance for current available antifungals, mainly driven by environmental fungicide use or long-term exposure to antifungals, in the setting of mould-active prophylaxis or for chronic antifungal infections, such as chronic pulmonary aspergillosis. Moreover, the incidence of breakthrough infections is increasing, because of the introduction of (mould-active) prophylaxis (1-4).
View Article and Find Full Text PDFPlant Dis
October 2024
University of Tsukuba, Fac. Life & Environ., 1-1-1 Tennoudai, Tsukuba, Ibaraki, Japan, 305-8572;
In recent years, increasingly stringent pesticide regulations have made the development of new chemistries challenging. Under these regulations, the new fungicide ipflufenoquin (FRAC Code 52) was first released in Japan. Its mode of action is new; it inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in the biosynthesis of pyrimidine-based nucleotides.
View Article and Find Full Text PDFJ Antimicrob Chemother
December 2024
Unit of Infectious Diseases, Internal Medicine Department, Elda General University Hospital-FISABIO, Ctra Elda-Sax s/n, CP 03600, Elda, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!